Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Given that use of GLP-1 RAs have been associated with muscle loss, an important question that remains is whether repeated GLP-1 RA use and cessation alter body composition in favour of fat mass relative to lean mass, pushing individuals with obesity closer to sarcopenic obesity
Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes
Psychoneuroendocrinology 137:105667 Verhoef SP, Meyer D, Westerterp KR (2011) Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake
Treatment with anti-somatostatin antibodies or co-infusion with a somatostatin receptor 2 antagonist eliminated the GLP- 1-mediated suppression of glucagon secretion [71]
All together, that means improved outcomes for both your teams well-being and your organizations bottom line
